Australia's CSL posts strong sales and revenues growth for 2016/17

Australian biotech firm CSL Limited (ASX: CSL) today announced a net profit after tax (NPAT) of $1,337 million (all figures US dollars) for the 12 months ended June 30, 2017. Underlying NPAT was up 24% and underlying earnings per share (EPS) grew 26%, both on a constant currency (CC) basis.

Revenue for the fiscal year was $6,923 million, a rise of 15% at CC. Earnings before interest and tax (EBIT) came in at $1,769 million, up 23% CC, and earnings per share were $2.94, an underlying increase of 26%.

At its CSL Behring business unit, the key growth driver was Privigen, the company’s intravenous immunoglobulin product for which demand has been strong in both the USA and Europe. Privigen sales grew at 21% at constant currency. Privigen’s exceptional performance was driven by significant growth in the Speciality Pharmacy segment, Privigen’s expanded indication to include its use in the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Europe as well as substantial market share gains due to competitor supply disruptions.